Neda Rezaee1, Carlotta Barbon1, Ahmed Zaki1, Jin He1, Bulent Salman1, Ralph H Hruban2, John L Cameron1, Joseph M Herman3, Nita Ahuja4, Anne Marie Lennon5, Matthew J Weiss6, Laura D Wood7, Christopher L Wolfgang8. 1. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3. Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Radiation Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Radiation Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Gastroenterology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. 6. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 7. Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: ldelong1@jhmi.edu. 8. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: cwolfga2@jhmi.edu.
Abstract
BACKGROUND: Non-invasive intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia and IPMN-associated invasive pancreatic ductal adenocarcinoma (PDAC) are frequently included under the term "malignancy". The goal of this study is to clarify the difference between these two entities. METHODS: From 1996 to 2013, data of 616 patients who underwent pancreatic resection for an IPMN were reviewed. RESULTS: The median overall survival for patients with IPMN with high-grade dysplasia (92 months) was similar to survival for patients with IPMN with low/intermediate-grade dysplasia (118 months, p = 0.081), and superior to that of patients with IPMN-associated PDAC (29 months, p < 0.001). IPMN-associated PDAC had lymph node metastasis in 53%, perineural invasion in 58%, and vascular invasion in 33%. In contrast, no lymph node metastasis, perineural or vascular invasion was observed with high-grade dysplasia. None of the patients with IPMN with high-grade dysplasia developed recurrence outside the remnant pancreas. In stark contrast 58% of patients with IPMN-associated PDAC recurred outside the remnant pancreas. The rate of progression within the remnant pancreas was significant in patients with IPMN with high-grade (24%) and with low/intermediate dysplasia (22%, p = 0.816). CONCLUSION: Non-invasive IPMN with high-grade dysplasia should not be considered a malignant entity. Compared to patients with IPMN with low/intermediate-grade dysplasia, those with high-grade dysplasia have an increased risk of subsequent development of PDAC in the remnant pancreas.
BACKGROUND:Non-invasive intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia and IPMN-associated invasive pancreatic ductal adenocarcinoma (PDAC) are frequently included under the term "malignancy". The goal of this study is to clarify the difference between these two entities. METHODS: From 1996 to 2013, data of 616 patients who underwent pancreatic resection for an IPMN were reviewed. RESULTS: The median overall survival for patients with IPMN with high-grade dysplasia (92 months) was similar to survival for patients with IPMN with low/intermediate-grade dysplasia (118 months, p = 0.081), and superior to that of patients with IPMN-associated PDAC (29 months, p < 0.001). IPMN-associated PDAC had lymph node metastasis in 53%, perineural invasion in 58%, and vascular invasion in 33%. In contrast, no lymph node metastasis, perineural or vascular invasion was observed with high-grade dysplasia. None of the patients with IPMN with high-grade dysplasia developed recurrence outside the remnant pancreas. In stark contrast 58% of patients with IPMN-associated PDAC recurred outside the remnant pancreas. The rate of progression within the remnant pancreas was significant in patients with IPMN with high-grade (24%) and with low/intermediate dysplasia (22%, p = 0.816). CONCLUSION: Non-invasive IPMN with high-grade dysplasia should not be considered a malignant entity. Compared to patients with IPMN with low/intermediate-grade dysplasia, those with high-grade dysplasia have an increased risk of subsequent development of PDAC in the remnant pancreas.
Authors: Sushanth Reddy; Christopher L Wolfgang; John L Cameron; Frederic Eckhauser; Michael A Choti; Richard D Schulick; Barish H Edil; Timothy M Pawlik Journal: Ann Surg Date: 2009-08 Impact factor: 12.969
Authors: George A Poultsides; Sushanth Reddy; John L Cameron; Ralph H Hruban; Timothy M Pawlik; Nita Ahuja; Ajay Jain; Barish H Edil; Christine A Iacobuzio-Donahue; Richard D Schulick; Christopher L Wolfgang Journal: Ann Surg Date: 2010-03 Impact factor: 12.969
Authors: Meena S Moran; Harrison X Bai; Eleanor E R Harris; Douglas W Arthur; Lisa Bailey; Jennifer R Bellon; Lisa Carey; Sharad Goyal; Michele Y Halyard; Kathleen C Horst; Shannon M MacDonald; Bruce G Haffty Journal: Breast J Date: 2011-11-23 Impact factor: 2.431
Authors: Nabil Wasif; David J Bentrem; James J Farrell; Clifford Y Ko; Oscar J Hines; Howard A Reber; James S Tomlinson Journal: Cancer Date: 2010-07-15 Impact factor: 6.860
Authors: Jin He; John L Cameron; Nita Ahuja; Martin A Makary; Kenzo Hirose; Michael A Choti; Richard D Schulick; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang Journal: J Am Coll Surg Date: 2013-02-06 Impact factor: 6.113
Authors: Antonio Pea; Jun Yu; Neda Rezaee; Claudio Luchini; Jin He; Marco Dal Molin; James F Griffin; Helen Fedor; Shahriar Fesharakizadeh; Roberto Salvia; Matthew J Weiss; Claudio Bassi; John L Cameron; Lei Zheng; Aldo Scarpa; Ralph H Hruban; Anne Marie Lennon; Michael Goggins; Christopher L Wolfgang; Laura D Wood Journal: Ann Surg Date: 2017-07 Impact factor: 12.969
Authors: Abdurrahman Kadayifci; Mustafa Atar; Michelle Yang; Carlos Fernandez-Del Castillo; Mari Mino-Kenudson; William R Brugge Journal: Surg Endosc Date: 2017-04-25 Impact factor: 4.584
Authors: Katherine E Poruk; James Griffin; Martin A Makary; Jin He; John L Cameron; Matthew J Weiss; Laura D Wood; Michael Goggins; Christopher L Wolfgang Journal: J Gastrointest Surg Date: 2018-09-04 Impact factor: 3.452
Authors: Vincent Bernard; Alexander Semaan; Jonathan Huang; F Anthony San Lucas; Feven C Mulu; Bret M Stephens; Paola A Guerrero; Yanqing Huang; Jun Zhao; Nabiollah Kamyabi; Subrata Sen; Paul A Scheet; Cullen M Taniguchi; Michael P Kim; Ching-Wei Tzeng; Matthew H Katz; Aatur D Singhi; Anirban Maitra; Hector A Alvarez Journal: Clin Cancer Res Date: 2018-11-01 Impact factor: 12.531
Authors: Elena Fernandez-Castañer; Maria Vila-Casadesus; Elena Vila-Navarro; Carolina Parra; Juan Jose Lozano; Antoni Castells; Meritxell Gironella Journal: Cancers (Basel) Date: 2021-05-14 Impact factor: 6.639
Authors: Naziheh Assarzadegan; Elizabeth Thompson; Kevan Salimian; Matthias M Gaida; Lodewijk A A Brosens; Laura Wood; Syed Z Ali; Ralph H Hruban Journal: Langenbecks Arch Surg Date: 2021-05-28 Impact factor: 2.895